DEPO-PROVERA (medroxyprogesterone acetate injectable suspension, USP) 1 Indications

Medical Information

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?


DEPO-PROVERA (medroxyprogesterone acetate injectable suspension, USP) is indicated for:

  • conception control (prevention of pregnancy)
  • treatment of endometriosis

DEPO-PROVERA should be used only if other treatments have been considered to be unsuitable or unacceptable and should be used for the shortest period of time possible.  It should be taken into consideration that the return to fertility following treatment with DEPO-PROVERA may be delayed (see 7 WARNINGS AND PRECAUTIONS).

Since loss of bone mineral density (BMD) may occur in females of child-bearing potential who use DEPO-PROVERA long-term (see 7 WARNINGS AND PRECAUTIONS), a risk/benefit assessment, which also takes into consideration the decrease in BMD that occurs during pregnancy and/or lactation, should be considered.  The risks and benefits of treatment should be carefully reevaluated on a regular basis in all users of this drug.

Although there are no studies addressing whether calcium and vitamin D may lessen bone mineral density (BMD) loss in women using DEPO-PROVERA, all patients should have adequate calcium and vitamin D intake. Cessation of smoking and regular weight bearing exercise should be discussed with all patients.  

1.1  Pediatrics 

  • Pediatrics (12-18 years): In adolescents, use of DEPO-PROVERA is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with DEPO-PROVERA during the critical period of bone accretion (see 7 WARNINGS AND PRECAUTIONS).

1.2 Geriatrics

  • Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use.